Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Early Stage Biopharma Financings Kept Up Multibillion-Dollar Pace In 2016

Executive Summary

Series A venture capital and seed funding rounds for biopharma firms in 2016 kept pace with the level of investment seen in 2015, excluding one major deal in 2015, laying the foundation for optimism regarding early-stage financings in 2017 for particularly innovative companies.

Advertisement

Related Content

VC Roundup: Flagship’s New Fund Designed To Raise Its Stake In Startups
Bayer/Versant Launch New Stem Cell Company With Massive Cash Injection
Lilly’s Solanezumab Fails, But The Surprise Would Have Been Success
Carrick Therapeutics Lays Foundation For 'Leading Oncology Business'
Hengrui Pursues Innovation Through New $100m US Spinoff
Record CStone Funding Heralds New Era For China Startups
Aptinyx Cashes In Post-Naurex Cache With $65m Series A
Boston Pharmaceuticals: A New Model To De-Risk Drugs
Naurex Spinout Aptinyx Launches After Allergan Deal
Allergan paying $560m for Naurex; stays quiet on rumored generics sale to Teva

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097951

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel